Health
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
Adam Feuerstein·STAT News·November 15, 2026

The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.
Read the full story at STAT News →